Understanding the roles of ARF and ADAR1 in triple-negative breast cancer
Antagonistic role of ARF and ADAR1 in triple-negative breast cancer
This study is looking at how two proteins, ARF and ADAR1, work together in triple-negative breast cancer to see how their loss affects the immune system's response, with the goal of finding new ways to treat the cancer and better predict how patients will respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11015927 on NIH RePORTER |
What this research studies
This research investigates the complex interactions between two proteins, ARF and ADAR1, in the context of triple-negative breast cancer (TNBC). It aims to uncover how the loss of ARF and p53 proteins affects the immune response in TNBC, particularly focusing on type I interferon signaling. By studying these interactions, the research seeks to identify new therapeutic targets and biomarkers that could predict patient responses to treatment. The approach includes defining the functional roles of ARF and ADAR1 and their impact on cancer cell behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who may benefit from novel therapeutic strategies.
Not a fit: Patients with non-triple-negative breast cancer or those who do not have a genetic predisposition related to ARF and ADAR1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies and biomarkers that improve treatment outcomes for patients with triple-negative breast cancer.
How similar studies have performed: While the specific interaction between ARF and ADAR1 in TNBC is novel, similar research has shown promise in targeting immune responses in cancer treatment.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Weber, Jason — Washington University
- Study coordinator: Weber, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.